About miRdetect
The number of cancer patients is rapidly increasing worldwide and an early detection of cancer is becoming more and more important. Early detection dramatically increases the probability for higher survival rates and ultimately curing cancer. Furthermore adoption of liquid biopsies for patients with advanced malignancies is very important. But current approaches are not sensitive, specific, and reliable enough.
miRdetect has developed an innovative test procedure that enables the early and exact detection of cancer. This is applicable to genetic material of any origin and has the potential for highly sensitive and robust molecular diagnostic assays. The method has been validated through a testicular cancer assay as a first example.
- Founding: 2016
- Focus : Manufacturer
- Industry : Diagnostics
Product portfolio of miRdetect
Here you will find miRdetect GmbH
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
